Benzothiazole compound and application thereof
Patent Information
- Application Number
- CN202380049622.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-24
- Filing Date
- 2023-06-21
- Publication Date
- 2025-02-28
AI Technical Summary
The existing Bcl-xL inhibitor A-1331852 has shortcomings in reducing platelet toxicity and improving killing specificity, and its physical and chemical properties are poor, affecting its safety and effectiveness in clinical application.
A new class of benzothiazole compounds has been developed with excellent physical and chemical properties and higher safety. It can significantly reduce platelet toxicity and selectively kill senescent cells and tumor cells within a larger safety window while reducing the impact on normal cells. Cell-killing side effects.
New benzothiazole compounds significantly improve water solubility and safety, reduce platelet toxicity, and effectively kill senescent cells and tumor cells at lower concentrations, reducing damage to normal cells and providing better treatments for aging-related diseases potential strategies.
Smart Images

Figure DSB0000210075740000011
Abstract
Description
Benzothiazole compounds and their applications Technical Field
[0001] The present invention relates to the field of medicine, and in particular to a benzothiazole compound capable of targeted killing of senescent cells, and its application in preventing or treating aging-related diseases. Background Art
[0002] With aging, the body's biological functions gradually decline, and the aging process is often accompanied by the onset of various age-related diseases. Therefore, developing effective intervention strategies for aging is crucial for extending the healthy lifespan of the elderly and reducing the incidence of age-related diseases. The accumulation of senescent cells in the body is a key driver of aging and age-related diseases. On the one hand, the senescence of some proliferating cells or stem cells leads to a decline in the body's regenerative capacity, affecting the body's recovery and normal function. More importantly, senescent cells secrete a large number of inflammatory factors, known as the senescence-associated secretory phenotype (SASP), which creates a chronic inflammatory microenvironment, accelerates the aging process, and promotes the development of age-related diseases. Studies have shown that the specific elimination of senescent cells through genetic methods or small chemical molecules can reduce chronic inflammation, enhance tissue repair capacity, improve symptoms of age-related diseases such as osteoarthritis and idiopathic pulmonary fibrosis, and alleviate the decline in physiological function in aging organisms. Therefore, selective elimination of senescent cells is a promising approach for treating age-related diseases and improving physiological function in the elderly.
[0003] Researchers have demonstrated that eliminating senescent cells in vivo can prolong lifespan and delay the onset of age-related diseases, providing a theoretical basis for strategies to target senescent cells for anti-aging and treatment of age-related diseases. Several small molecule compounds, also known as senolytics, have been reported to selectively eliminate senescent cells. Due to the heterogeneity of senescent cells, while these senolytics can achieve a degree of selective killing of senescent cells, there remains room for improvement in reducing toxicity and increasing specificity. Early senolytics primarily targeted key components of the senescent cell anti-apoptotic pathway (SCAP), inducing cell death by blocking anti-apoptotic signaling in senescent cells. Compared to normal cells, senescent cells exhibit significantly increased expression of the anti-apoptotic proteins BCL2 / BCL-XL, which antagonize the activity of pro-apoptotic proteins such as Bax, rendering them resistant to apoptosis. ABT263 (navitoclax), a dual inhibitor of the classic anti-apoptotic proteins BCL2 / BCL-XL, was subsequently shown to specifically induce apoptosis in senescent cells.
[0004] A-1331852 (CAS1430844-80-6) is a small molecule inhibitor specific for the Bcl-xL protein. In addition to its excellent anti-Bcl-xL cytotoxicity against cancer cells that rely on Bcl-xL, it also exhibits high activity against senescent cells. However, due to its extremely potent inhibitory effect on Bcl-xL, A-1331852 kills platelets at relatively low concentrations and exhibits significant platelet toxicity under in vivo conditions, limiting its clinical application. Furthermore, the physicochemical properties of A-1331852 could be improved. For example, its solubility in water is low, and its oral bioavailability in rats is only approximately 11%. Due to these limitations, A-1331852 is used only as a tool compound in research studies, serving as a superior Bcl-xL-specific inhibitor.
[0005] Currently, there is a lack of a Bcl-xL inhibitor that not only has a strong inhibitory effect on Bcl-xL but also has excellent physicochemical properties and better safety.
[0006] Summary of the Invention
[0007] To address at least one of the technical problems existing in the prior art, the present invention provides a novel class of benzothiazole compounds that significantly reduce platelet toxicity, selectively kill senescent cells and tumor cells within a wider safety window, while reducing the side effects of killing normal cells, thereby achieving higher selectivity and safety. Furthermore, the compounds of the present invention exhibit excellent physical and chemical properties, particularly significantly improved water solubility.
[0008] In a first aspect, the present application provides a benzothiazole compound having a structure shown in Formula I:
[0009] in,
[0010] R1 and R2 are independently selected from C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl, C2-C20 heteroalicyclic, wherein C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, wherein CH2 can be selected from one of -O-, -S-, -SO2-, -C(O)- and -NR3- or more than two groups are replaced, wherein the C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic groups are optionally replaced by halogen atoms, cyano, nitro, C6-C20 aryl, C1-C20 heteroaryl, C1-C10 alkoxy, C6-C20 aryloxy, C2-C20 heteroalicyclic groups, amino, hydroxyl, thiol, -substituted by one or more substituents in NR4R5; or
[0011] R1 and R2 together with the nitrogen atom to which they are attached constitute a heteroalicyclic group, preferably a C2-C20 heteroalicyclic group; or
[0012] R1 is hydrogen, and R2 is selected from C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic, wherein C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, wherein CH2 can be replaced by one or more groups selected from -O-, -S-, -SO2-, -C(O)- and -NR3-, and the ... The C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl, or C2-C20 heteroalicyclic group is substituted with a halogen atom, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, C1-C10 alkoxy, C6-C20 aryl, C1-C20 heteroaryl, C2-C20 heteroalicyclic group, C1-C10 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl group, and the substituents at at least two positions together form an aliphatic ring, heteroalicyclic ring, aromatic ring, or heteroaromatic ring;
[0013] R3, R4 and R5 are independently selected from hydrogen, aryl, heteroaryl, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl, wherein the aryl and heteroaryl groups are optionally substituted with halogen atoms, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, alkoxy, aryl, heteroaryl, heteroalicyclic, C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl or C2-C8 alkynyl, wherein the substituents at at least two positions together form an alicyclic, heteroalicyclic, aromatic or heteroaromatic ring;
[0014] L is a C1-C6 alkylene group, which is optionally substituted by a halogen atom, a hydroxyl group, a thiol group, an amino group, a nitro group, a cyano group, a carboxyl group, an acyl group, a C1-C10 alkoxy group, a C6-C20 aryl group, a C1-C20 heteroaryl group, a C2-C20 heteroalicyclic group, a C1-C10 alkyl group, a C3-C8 cycloalkyl group, a C2-C8 alkenyl group, or a C2-C8 alkynyl group;
[0015] R is an adamantyl group, which is optionally substituted with a halogen atom, a hydroxyl group, a mercapto group, an amino group, a nitro group, a cyano group, a carboxyl group, an acyl group, a C1-C10 alkoxy group, a C6-C20 aryl group, a C1-C20 heteroaryl group, a C2-C20 heteroalicyclic group, a C1-C10 alkyl group, a C3-C8 cycloalkyl group, a C2-C8 alkenyl group, or a C2-C8 alkynyl group;
[0016] R a 、R b 、R c 、R d 、R e 、R f 、R g 、Rh 、R i 、R j 、R k 、R l 、R m 、R p 、R q 、R z Each is independently selected from hydrogen, halogen-substituted or unsubstituted C1-C8 alkyl, halogen-substituted or unsubstituted C3-C8 cycloalkyl, halogen-substituted or unsubstituted C2-C8 alkenyl, halogen-substituted or unsubstituted C2-C8 alkynyl, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, an acyl group, a halogen-substituted or unsubstituted C2-C8 alkoxy group.
[0017] Pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopic compounds (preferably deuterated compounds) or prodrugs of the benzothiophene compound shown in Formula I are also within the scope of protection of this application. Therefore, the present application also provides pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopic compounds (preferably deuterated compounds) or prodrugs of the benzothiophene compound shown in Formula I.
[0018] In some embodiments, the compound is represented by Formula II:
[0019] In formula II, the definitions of R1 and R2 are the same as those in formula I.
[0020] In some embodiments, in Formula I and / or Formula II, R1 and R2 together with the N atom to which they are attached constitute a C2-C20 heteroalicyclic group, such as a C2-C10 heteroalicyclic group, and the ring of the C2-C20 heteroalicyclic group optionally additionally contains 1 or 2 heteroatoms selected from N or O.
[0021] In some embodiments, the C2-C20 heteroalicyclic group is optionally replaced by a halogen atom, a cyano group, a nitro group, a C6-C10 aryl group, a C1-C10 heteroaryl group, a C1-C6 alkoxy group, a C6-C10 aryloxy group, a C2-C10 heteroalicyclic group, an amino group, a hydroxyl group, a thiol group, a carbonyl group, a carboxyl group, an acyl group, -NR4R5 is substituted by one or more substituents, R4 and R5 are independently selected from hydrogen, C6-C10 aryl, C1-C10 heteroaryl, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl, and the aryl and heteroaryl are optionally substituted by halogen atoms, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, C1-C8 alkoxy, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic group, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C6 alkenyl or C2-C8 alkynyl, optionally, wherein the substituents at at least two positions together constitute a C3-C10 alicyclic ring, C2-C10 heteroalicyclic ring, C6-C10 aromatic ring or C1-C10 heteroaromatic ring.
[0022] In some embodiments, the C2-C20 heteroalicyclic group is optionally selected from a halogen atom, a hydroxyl group, a thiol group, an amino group, a nitro group, a cyano group, a C1-C10 alkoxy group, a C1-C10 alkyl group, a C3-C8 cycloalkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, Substituents are substituted, R4 and R5 are independently selected from hydrogen and C1-C6 alkyl.
[0023] In some embodiments, the C2-C8 heteroalicyclic group is optionally substituted by halogen, -NH2, -OH, -NO2, carbonyl, -CH2OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
[0024] In some embodiments, R1 and R2 are independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic, wherein CH2 in C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl can be selected from -O-, -S-, -SO2-, -C(O)- and -NR3 -, wherein one or more groups are replaced by a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C6-C10 aryl group, a C1-C10 heteroaryl group and a C2-C10 heteroalicyclic group, and the C1-C6 alkyl group, the C3-C6 cycloalkyl group, the C2-C6 alkenyl group, the C2-C6 alkynyl group, the C6-C10 aryl group, the C1-C10 heteroaryl group and the C2-C10 heteroalicyclic group are optionally replaced by a halogen atom, a cyano group, a nitro group, a C6-C10 aryl group, a C1-C10 heteroaryl group, a C1-C6 alkoxy group, a C6-C10 aryloxy group, a C2-C10 heteroalicyclic group, an amino group, a hydroxyl group, a thiol group, -NR4R5 is substituted by one or more substituents, R3, R4 and R5 are independently selected from hydrogen, C6-C10 aryl, C1-C10 heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl and C2-C6 alkynyl, and the aryl and heteroaryl are optionally substituted by halogen atoms, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, C1-C6 alkoxy, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic group, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl or C2-C6 alkynyl, wherein the substituents at at least two positions together constitute a C3-C10 alicyclic ring, C2-C10 heteroalicyclic ring, C6-C10 aromatic ring or C1-C10 heteroaromatic ring.
[0025] In some embodiments, the benzothiophene compound is represented by Formula III:
[0026] In formula III, R2 is C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic, wherein CH2 in C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl can be selected from -O-, -S-, -SO2-, -C(O)- and -NR3-. or more than two groups are replaced by the C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic groups, which are replaced by halogen atoms, cyano, nitro, C6-C20 aryl, C1-C20 heteroaryl, C1-C10 alkoxy, C6-C20 aryloxy, C2-C20 heteroalicyclic groups, amino, hydroxyl, thiol, -NR4R5 is substituted by one or more substituents; R3, R4 and R5 are independently selected from hydrogen, C6-C10 aryl, C1-C10 heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl and C2-C6 alkynyl, and the aryl and heteroaryl are optionally substituted by halogen atoms, hydroxyl, sulfhydryl, amino, nitro, cyano, carboxyl, acyl, C1-C6 alkoxy, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic group, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl or C2-C6 alkynyl, wherein the substituents at at least two positions together constitute a C3-C10 alicyclic ring, C2-C10 heteroalicyclic ring, C6-C10 aromatic ring or C1-C10 heteroaromatic ring.
[0027] In some embodiments, the heteroalicyclic group or heteroalicyclic ring is selected from: substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted piperazin-2-onyl, substituted or unsubstituted pyrrolidinyl and substituted or unsubstituted imidazolinyl.
[0028] In some embodiments, R1 and / or R2 are selected from methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heterocyclyl, 6-membered heterocyclyl, 5-membered carbocyclyl or 6-membered carbocyclyl, and each heteroaryl and each heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and each group is independently optionally substituted with -F, -Cl, -Br, -I, -NH2, -OH, -NO2, carbonyl, -CH2-OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
[0029] In some embodiments, R1 and / or R2 are selected from 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heterocyclyl, 6-membered heterocyclyl, 5-membered carbocyclyl or 6-membered carbocyclyl, and each heteroaryl and each heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and each group is independently optionally substituted with -F, -Cl, -Br, -I, -NH2, -OH, -NO2, carbonyl, =O, -CH2-OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
[0030] In some embodiments, R1 and R2, together with the N atom to which they are attached, constitute a 6-membered aryl, a 5-membered heteroaryl, a 6-membered heteroaryl, a 5-membered heterocyclyl, a 6-membered heterocyclyl, a 5-membered carbocyclyl, or a 6-membered carbocyclyl, and each heteroaryl and each heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and each group is independently optionally substituted with -F, -Cl, -Br, -I, -NH2, -OH, -NO2, carbonyl, =O, -CH2-OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, or isopropoxy.
[0031] In some embodiments, R1 and R2 together with the nitrogen atom to which they are attached form a C2-C20 heteroalicyclic group.
[0032] In some embodiments, the C2-C20 heteroalicyclic group is selected from a C4-C20 heteroalicyclic group.
[0033] In some embodiments, the C4-C20 heteroalicyclic group is selected from substituted or unsubstituted morpholinyl, substituted or unsubstituted piperidinyl, or substituted or unsubstituted piperazinyl.
[0034] In some embodiments, the C4-C20 heteroalicyclic group is selected from the group shown below:
[0035] R' independently represents no substituent, a single substituent or multiple substituents, each substituent is independently selected from deuterium, hydroxyl, halogen, NH2, carboxyl (-COOH), C1-C6 alkyl, halogen-substituted C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl, benzyl;
[0036] L2 is absent or C1-C6 alkylene, halogen, hydroxyl, C1-C6 alkoxy substituted C1-C6 alkylene, preferably methylene, ethylene, propylene;
[0037] R6 is H, deuterium, halogen, hydroxyl, NH2, carboxyl (-COOH), -CONH2, sulfonic acid (-SO3H), -SO2-C1-C6 chain alkyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl or benzyl.
[0038] In some embodiments, the compound has a structure shown in Formula I-1, Formula I-2, Formula I-3, Formula I-4 or Formula I-5,
[0039] L1 is absent or -NHL3-, L3 is absent or L2 is absent C1-C6 alkylene, halogen, hydroxyl, C1-C6 alkoxy substituted C1-C6 alkylene, preferably methylene, ethylene, propylene;
[0040] L2 is a C1-C6 alkylene group not substituted by a C1-C6 alkylene group, a halogen group, a hydroxyl group, or a C1-C6 alkoxy group, preferably a methylene group, an ethylene group, or a propylene group;
[0041] R6 is H, deuterium, halogen, hydroxyl, NH2, carboxyl (-COOH), -CONH2, sulfonic acid (-SO3H), -SO2-C1-C6 chain alkyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl or benzyl;
[0042] R' independently represents no substituent, a single substituent or multiple substituents, each substituent is independently selected from R6 is H, deuterium, halogen, hydroxyl, NH2, carboxyl (-COOH), -CONH2, sulfonic acid (-SO3H), -SO2-C1-C6 chain alkyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl or benzyl;
[0043] Other symbols are defined the same as in Formula I.
[0044] In some embodiments, R' independently represents no substituent, a single substituent, or multiple substituents, each substituent being independently selected from deuterium, hydroxyl, halogen, NH2, carboxyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl, benzyl.
[0045] In some embodiments, R a 、R b 、R c 、R d Each is independently selected from hydrogen or C1-C6 alkyl. e 、R f 、R g Each is independently selected from hydrogen or C1-C6 alkyl. h 、R i 、R j 、R k 、R l 、R m Each is independently selected from hydrogen or C1-C6 alkyl. p 、R q 、R zEach is independently selected from hydrogen or C1-C6 alkyl. a 、R b 、R c 、R d 、R e 、R f 、R g 、R h 、R i 、R j 、R k 、R l 、R m 、R p 、R q 、R z All are hydrogen.
[0046] In some embodiments, L is methylene.
[0047] In some embodiments, R Z It's methyl.
[0048] In some embodiments, R is
[0049] In some embodiments, L1 is absent.
[0050] In some embodiments, R6 is H, halogen, hydroxy, NH2, carboxyl, C1-C3 alkyl, halogen-substituted C1-C3 alkyl or hydroxy-substituted C1-C3 alkyl.
[0051] In some embodiments, R6 is
[0052] In a more specific embodiment, the benzothiazole compound represented by Formula I is selected from the following compounds:
[0053] The second aspect of the present application provides a pharmaceutical composition, which comprises the compound described in the first aspect or its pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled compound or prodrug, and a pharmaceutically acceptable excipient.
[0054] The third aspect of the present application provides a method for preventing or treating aging-related diseases, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of the first aspect or its pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer or prodrug, or the pharmaceutical composition of the second aspect. In particular, the disease is selected from diseases associated with the accumulation of senescent cells, and the disease is preferably selected from idiopathic pulmonary fibrosis, pulmonary fibrosis, liver fibrosis, renal fibrosis, viral-induced inflammation and tissue fibrosis and atrophy of the upper respiratory tract and lungs, cystic fibrosis, myelofibrosis, myocardial fibrosis, skin fibrosis, interstitial lung disease, fibrosing pancreatitis, retinopathy of prematurity, macular degeneration, diabetic macular edema, diabetic retinopathy, age-related macular degeneration, wet age-related macular degeneration, dry age-related macular degeneration, glaucoma, sickle cell retinopathy, ischemic arteritic neuropathy, keratitis sicca, Fuch's corneal dystrophy, presbyopia, cataracts, degenerative vitreous disorders including vitreomacular traction syndrome, macular hole, retinal tear, retinal detachment, proliferative vitreoretinopathy, osteoarthritis , herniated disc, osteoporosis, Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic obstructive pulmonary disease, diabetes, diabetic nephropathy, scars, superficial scars or flat scars, cord-like scars or contracture scars, webbed scars, depressed scars, atrophic scars, bridge-like scars and scars with hypertrophic features, keloids, scar cancer, scleroderma, morphea, scleroderma bands, guttate scleroderma, acroscleroderma, diffuse scleroderma, CREST syndrome, acute coronary syndrome, myocardial infarction, stroke, hypertension, obesity, fat dysfunction, coronary artery disease, cerebrovascular disease, periodontal disease, cancer treatment-related disabilities such as atrophy and fibrosis in various tissues, brain and heart damage and treatment-related myelodysplastic syndrome, promyelocytic syndrome, ataxia-telangiectasia, Fanconi anemia, Friedreich's ataxia, One or more of dyskeratosis congenita, aplastic anemia, aneurysm, inflammatory bowel disease, lipoatrophy, renal transplant failure, sarcopenia, wound healing, alopecia, cardiomyocyte hypertrophy, glomerulosclerosis, and cancer.
[0055] The fourth aspect of the present application provides the use of the compound described in the first aspect or its pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled compound or prodrug, or the pharmaceutical composition described in the second aspect in the preparation of a drug for preventing or treating aging-related diseases. In particular, the disease is selected from diseases associated with the accumulation of senescent cells, and the disease is preferably selected from idiopathic pulmonary fibrosis, pulmonary fibrosis, liver fibrosis, renal fibrosis, viral-induced inflammation and tissue fibrosis and atrophy of the upper respiratory tract and lungs, cystic fibrosis, myelofibrosis, myocardial fibrosis, skin fibrosis, interstitial lung disease, fibrosing pancreatitis, retinopathy of prematurity, macular degeneration, diabetic macular edema, diabetic retinopathy, age-related macular degeneration, wet age-related macular degeneration, dry age-related macular degeneration, glaucoma, sickle cell retinopathy, ischemic arteritic neuropathy, keratitis sicca, Fuch's corneal dystrophy, presbyopia, cataracts, degenerative vitreous disorders including vitreomacular traction syndrome, macular hole, retinal tear, retinal detachment, proliferative vitreoretinopathy, osteoarthritis, herniated disc, osteoporosis, Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic obstructive pulmonary disease, diabetes, Diabetes, diabetic nephropathy, scars, superficial or flat scars, cord-like or contracture scars, webbed scars, depressed scars, atrophic scars, bridge-like and hypertrophic scars, hypertrophic scars, keloids, scar cancer, scleroderma, morphea, scleroderma zona flexica, guttate scleroderma, acroscleroderma, diffuse scleroderma, CREST syndrome, acute coronary syndrome, myocardial infarction, stroke, hypertension, obesity, adipose tissue dysfunction, coronary artery disease, cerebrovascular disease , periodontal disease, cancer treatment-related disabilities such as atrophy and fibrosis in various tissues, brain and heart damage and treatment-related myelodysplastic syndrome, promyelocytic syndrome, ataxia telangiectasia, Fanconi anemia, Friedreich's ataxia, dyskeratosis congenita, aplastic anemia, aneurysm, inflammatory bowel disease, lipoatrophy, renal transplant failure, sarcopenia, wound healing, alopecia, cardiomyocyte hypertrophy, glomerulosclerosis, and one or more of cancer.
[0056] The novel benzothiophene compound provided in the present application has improved physicochemical properties and safety compared to A-1331852, has low platelet toxicity, and has better solubility. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] FIG1 is a test result of platelet toxicity of the compound in mice.
[0058] FIG2 shows the test results of the killing effect of the compound on different types of normal and senescent cells.
[0059] Figure 3 shows that intravitreal (IVT) administration of RX001-RX006 and RX301 resulted in statistically significant improvements in avascular zone and vascular proliferation.
[0060] Figure 4 shows the results of intravitreal (IVT) administration of RX001, RX002, RX003 and RX301 in the diabetic macular model of retinal and choroidal vascular leakage, which can improve vascular permeability at this dose level.
[0061] FIG5 shows the statistically significant improvement in fluorescence intensity indices of the CNV macular model after intravitreal (IVT) administration of RX001, RX002, RX003, and RX301.
[0062] Figure 6 shows that intraperitoneal (IP) administration of RX001, RX002, RX003, and RX301 resulted in statistically significant improvements in WBC, HYP, and pathology scores in an IPF model.
[0063] FIG7 shows that intra-articular injection of RX001, RX002, RX003 and RX301 resulted in statistically significant improvements in plantar mechanical pain threshold and pathological scores of safranin fast green staining in an osteoarthritis (OA) model.
[0064] FIG8 shows that intraperitoneal administration of RX001, RX002, RX003, and RX301 resulted in statistically significant improvement in Aβ42 pathogenic protein markers in an Alzheimer's disease (AD) mouse model.
[0065] FIG9 shows that intraperitoneal (IP) administration of RX001 and RX301 resulted in statistically significant improvements in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and pathology scores in a liver fibrosis model.
[0066] FIG10 shows that topical application of RX001, RX002, RX003, and RX301 resulted in statistically significant improvements in epidermal thickness scores in a naturally aged mouse model.
[0067] FIG11 shows that intraperitoneal (IP) administration of RX001 and RX301 resulted in statistically significant improvements in serum creatinine (Cr) and urea nitrogen (BUN) levels and pathology in a renal fibrosis model.
[0068] FIG12 shows that administration of RX001 and RX301 resulted in statistically significant improvement in the scar hyperplasia index in the rabbit ear hypertrophic scar model. DETAILED DESCRIPTION
[0069] The present invention is described in detail below with reference to the examples and accompanying drawings. These examples are based on the present invention as a technical solution and provide detailed implementation plans and processes. However, the implementation plans provided herein are exemplary and intended to explain the present invention, and are not to be construed as limiting the present invention. Conditions and methods not specified in the following examples were performed conventionally.
[0070] definition
[0071] The term "alkyl" refers to an aliphatic hydrocarbon group, which can be a branched or straight chain alkyl group. Depending on the structure, the alkyl group can be a monovalent group or a divalent group (i.e., an alkylidene group). In the present invention, the alkyl group is preferably an alkyl group having 1 to 8 carbon atoms, more preferably a "low alkyl group" having 1 to 6 carbon atoms, and even more preferably an alkyl group having 1 to 4 carbon atoms. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, amyl, hexyl, etc. It should be understood that "alkyl" mentioned herein includes all possible configurations and conformations of the alkyl group, for example, "propyl" mentioned herein includes n-propyl and isopropyl, "butyl" includes n-butyl, isobutyl and tert-butyl, and "pentyl" includes n-pentyl, isopropyl, neopentyl, tert-pentyl, and penta-3-yl, etc.
[0072] The term "alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined herein. Typical alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like.
[0073] The term "cycloalkyl" refers to a monocyclic or polycyclic radical containing only carbon and hydrogen. Cycloalkyl includes a group having 3-12 ring atoms. According to structure, cycloalkyl can be a monovalent group or a divalent group (e.g., cycloalkylidene). In the present invention, cycloalkyl is preferably a cycloalkyl having 3-8 carbon atoms, more preferably a "low cycloalkyl" having 3-6 carbon atoms. The example of cycloalkyl includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and adamantyl.
[0074] The term "aryl" refers to an aromatic ring in which each of the atoms forming the ring is a carbon atom. The aryl ring can be composed of five, six, seven, eight, nine, or more than nine atoms. An aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, phenanthrenyl, anthracenyl, fluorenyl, and indenyl. Depending on the structure, an aryl group can be a monovalent group or a divalent group (i.e., an arylene group).
[0075] The term "heteroaryl" refers to an aromatic group that includes one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. The N-containing "heteroaryl" portion refers to an aromatic group in which at least one skeletal atom on the ring is a nitrogen atom. Depending on the structure, a heteroaryl group can be a monovalent group or a divalent group (i.e., a heteroarylidene group). Examples of heteroaryl groups include, but are not limited to, pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, isoindole, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, and furopyridinyl.
[0076] As used herein, the term "alicyclic group" or "cycloalkyl" refers to a non-aromatic ring consisting of three or more carbon atoms, wherein two adjacent carbon atoms within the ring may have a single bond, a double bond, or a triple bond, and the number of rings may be one or more. Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexenyl, cyclopentenyl, and cyclohexadienyl.
[0077] As used herein, the term "heterocycloalkyl" or "heteroalicyclic" or "heteroalicyclic" refers to a non-aromatic ring in which one or more of the atoms forming the ring is a heteroatom selected from nitrogen, oxygen and sulfur. A heterocycloalkyl group may be composed of three, four, five, six, seven, eight, nine or more atoms. A heterocycloalkyl group may be optionally substituted. Examples of heteroalicyclic groups include, but are not limited to, lactams, lactones, cyclic imines, cyclic thioimides, cyclic carbamates, tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,3-oxathiinane, 1,4-oxathiinane, 1,4-oxathiinane, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbital Acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, imidazolidine, pyrrolidone, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine and 1,3-oxathiolane. Depending on the structure, the heteroalicyclic group can be a monovalent group or a divalent group (i.e., a heterocycloalkylene group).
[0078] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.
[0079] The term "carbonyl" refers to an organic functional group composed of two atoms, carbon and oxygen, connected by a double bond (C=O).
[0080] The term "optionally" means that one or more of the subsequently described events may or may not occur, and includes both events that occur and events that do not occur.
[0081] The salts that may be formed by the compounds of the present invention also fall within the scope of the present invention. Unless otherwise indicated, the compounds of the present invention are understood to include their salts. The term "salt" as used herein refers to acidic or basic salts formed with inorganic or organic acids and bases. In addition, when the compound of the present invention contains a basic fragment, it includes but is not limited to pyridine or imidazole, and contains an acidic fragment, including but not limited to carboxylic acid, the zwitterions ("inner salts") that may be formed are included within the scope of the term "salt". Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, for example, in separation or purification steps during the preparation process. The compounds of the present invention may form salts, for example, compound I reacts with a certain amount, such as an equivalent amount, of an acid or base, salts out in a medium, or is obtained by freeze-drying in an aqueous solution.
[0082] The compounds of the present invention contain basic moieties, including but not limited to amines or pyridine or imidazole rings, which may form salts with organic or inorganic acids. Typical acids that can form salts include acetates (e.g., acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipates, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphor, camphorsulfonate, cyclopentanepropionate, diglycolate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide,
[0014] Examples of the present invention include, for example, hydroxyethylsulfonates, lactates, maleates, methanesulfonates, naphthalenesulfonates (e.g., 2-naphthalenesulfonate), nicotinates, nitrates, oxalates, pectinates, persulfates, phenylpropionates (e.g., 3-phenylpropionate), phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (e.g., with sulfuric acid), sulfonates, tartrates, thiocyanates, toluenesulfonates such as p-toluenesulfonate, dodecanoates, and the like.
[0083] Certain compounds of the present invention may contain acidic moieties, including but not limited to carboxylic acids, which may form salts with various organic or inorganic bases. Typical base-forming salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, and salts formed with organic bases (e.g., organic amines), such as benzathine, dicyclohexylamine, hepamine (salt formed with N,N-di(dehydroabietyl)ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glucamide, tert-butylamine, and salts formed with amino acids such as arginine, lysine, and the like. Basic nitrogen-containing groups can react with halide quaternary ammonium salts, such as small molecular alkyl halides (such as chlorides, bromides and iodides of methyl, ethyl, propyl and butyl), dialkyl sulfates (such as dimethyl sulfate, diethyl sulfate, dibutyl sulfate and dipentyl sulfate), long chain halides (such as chlorides, bromides and iodides of decyl, dodecyl, tetradecyl and tetradecyl), aralkyl halides (such as benzyl and phenyl bromide), etc.
[0084] Prodrugs and solvates of the compounds of the present invention are also within the scope of this invention. The term "prodrug" herein refers to a compound that undergoes chemical transformation by metabolic or chemical processes to produce a compound, salt, or solvate of the present invention when treating a related disease. "Solvate" refers to a solvent addition form containing a stoichiometric or non-stoichiometric amount of solvent. Some compounds tend to capture a fixed molar ratio of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate; if the solvent is an alcohol, the solvate formed is an alcoholate. The combination of one or more water molecules with a molecule of a substance forms a hydrate, in which the water remains in its molecular state H2O. Non-limiting examples of solvates include ethanol solvates, acetone solvates, and the like.
[0085] The compounds, salts or solvates of the present invention may exist in tautomeric forms (such as amides and imino ethers). All such tautomers are part of the present invention.
[0086] All stereoisomers of the compounds (e.g., those that may exist due to asymmetric carbon atoms for various substitutions), including enantiomeric and diastereomeric forms, are contemplated by the present invention. Individual stereoisomers of the compounds of the present invention may not exist with other isomers (e.g., as a pure or substantially pure optical isomer having a particular activity), or may be mixtures, such as racemates, or mixtures with all other stereoisomers or portions thereof. The chiral centers of the present invention have either S or R configurations, as defined by the 1974 recommendations of the International Union of Pure and Applied Chemistry (IUPAC). Racemic forms can be resolved by physical methods, such as fractional crystallization, or by crystallization of diastereomers derived from them, or by separation by chiral column chromatography. Individual optical isomers can be obtained from the racemate by suitable methods, including but not limited to conventional methods, such as salt formation with an optically active acid followed by recrystallization.
[0087] The compounds of the present invention, obtained by sequential preparation, isolation, and purification, are described in the text to a concentration of 90% or greater by weight, for example, 95% or greater, or 99% or greater ("very pure" compounds). Such "very pure" compounds of the present invention are also considered part of the present invention.
[0088] All configurational isomers of the compounds of the present invention are encompassed, whether in mixture, pure or very pure form. The definition of the compounds of the present invention includes both cis (Z) and trans (E) olefin isomers, as well as cis and trans isomers of carbocyclic and heterocyclic rings.
[0089] Throughout the specification, groups and substituents may be chosen to provide stable fragments and compounds.
[0090] Specific functional groups and chemical term definitions are detailed below. For the purposes of this invention, chemical elements are referred to in the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th The definitions of specific functional groups are consistent with those in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito, 1999, which is incorporated by reference in its entirety.
[0091] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention encompasses all compounds, including their cis and trans isomers, R and S enantiomers, diastereomers, (D) isomers, (L) isomers, racemic mixtures, and other mixtures. Additionally, asymmetric carbon atoms may represent substituents, such as alkyl groups. All isomers and mixtures thereof are encompassed by the present invention.
[0092] According to the present invention, mixtures of isomers can contain various ratios of isomers. For example, mixtures containing only two isomers can have the following ratios: 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0. All ratios of isomers are within the scope of the present invention. Similar ratios, as well as ratios for more complex mixtures of isomers, are readily understood by those skilled in the art and are also within the scope of the present invention.
[0093] The present invention also includes isotopically labeled compounds that are equivalent to the original compounds disclosed herein. However, in practice, it is common for one or more atoms to be replaced by atoms having a different atomic mass or mass number. Examples of isotopes of the compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine isotopes, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, which contain isotopes or other isotopic atoms of the above compounds are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as 3 H and 14 Radioisotopes of C are also included and are useful in tissue distribution experiments of drugs and substrates. 3 H and carbon-14, i.e. 14 C, their preparation and detection are relatively easy. It is the first choice among isotopes. In addition, heavier isotope substitutions such as deuterium, i.e. 2H, due to its excellent metabolic stability, has advantages in certain therapeutics, such as increasing half-life in vivo or reducing dosage, and therefore, may be preferred in some cases. Isotopically labeled compounds can be prepared using conventional methods by replacing readily available isotopically labeled reagents with non-isotopic reagents using the protocols disclosed in the examples.
[0094] If a synthesis of a specific enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, followed by separation of the resulting diastereomeric mixture and removal of the chiral auxiliary to obtain the pure enantiomer. Alternatively, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, diastereomeric salts can be formed with a suitable optically active acid or base, followed by separation by conventional means such as fractional crystallization or chromatography to obtain the pure enantiomer.
[0095] As described herein, the compounds of the present invention may be substituted with any number of substituents or functional groups to expand their scope. Generally, the term "substituted," whether preceded or followed by the term "optionally," in formulas of the present invention including substituents, refers to the replacement of a hydrogen radical with a substituent of the specified structure. When multiple positions in a particular structure are substituted with multiple substituents of the specified structure, the substituents may be the same or different at each position. As used herein, the term "substituted" includes all permissible substitutions in organic compounds. Broadly speaking, permissible substituents include acyclic, cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. For example, heteroatoms of nitrogen may be substituted with hydrogen or any of the permissible organic compounds described above to supplement their valences. Furthermore, the present invention is not intended to limit the permissible substitutions in any way to organic compounds. The present invention recognizes that combinations of substituents and variables are advantageous for providing stable compounds for the treatment of diseases. As used herein, the term "stable" refers to compounds that are stable and maintain the structural integrity of the compound over a period of time sufficient to be detected, preferably over a period of time sufficient to be effective, as used herein for the purposes described above.
[0096] Example 1 Synthesis of Compound RX001
[0097] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 ml of DMF. TBTU (O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate) (49 mg, 0.1519 mmol) and DIPEA (20 mg, 0.1519 mmol) were added, followed by compound B (21 mg, 0.1823 mmol). The reaction was allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 ml) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 755.5 [M+H]+; 1 H NMR (400MHz, CDCl3) δ11.34(s,1H),7.96-7.74(m,1H),7.62-7.48(m,1H),7.39(m,2H ),7.31(m,2H),7.28-7.21(m,2H),7.18(m,1H),6.81(d,1H),5.00(s,2H),4.00(m,2H) ,3.79-3.68(m,2H),3.68-3.52(m,2H),3.12(t,J=5.1Hz,2H),3.01(m,2H),2.32(m,4 H),2.19(d,J=4.1Hz,3H),2.13-2.03(m,2H),2.00(s,3H),1.66(m,12H),1.01(t,3H).
[0098] Example 2 Synthesis of Compound RX002
[0099] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (49 mg, 0.1519 mmol) and DIPEA (20 mg, 0.1823 mmol) were added. Compound B (24 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 770.5 [M+H]+; 1H NMR (400MHz, CDCl3) δ7.91-7.83(d,1H),7.60-7.31(m,7H),7.25(m,1H),6.79(d,J=8.8Hz,1 H),5.04(s,2H),4.54(d,J=13.3Hz,1H),3.99(q,J=5.8Hz,2H),3.77(m,2H),3.72(s,2H),3. 60(t,J=6.5Hz,2H),3.34(d,J=13.3Hz,1H),3.04(t,J=6.0Hz,2H),2.74(t,1H),2.51(t,1H) ,2.19(s,3H),2.00(s,3H),1.90-1.85(m,2H),1.78-1.60(m,12H),1.38(m,2H),1.04(m,1H).
[0100] Example 3 Synthesis of Compound RX003
[0101] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (35 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 831.3 [M+H]+; 1 H NMR (400MHz, CDCl3) δ7.76(d,J=7.7Hz,1H),7.63(d,J=7.6Hz,2H),7.50-7.30(m,10H),7.28-7.24(m,1H),6.94(d,J=8.7Hz,1H),5. 17(s,2H),3.90(m,3H),3.71(s,4H),3.07(t,J=5.9Hz,2H),2.97(s,2H),2.29(s,2H),2.07(s,3H),1.99(m,7H),1.75-1.56(m,12H).
[0102] Example 4 Synthesis of Compound RX004
[0103] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (18 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 741.5 [M+H]+; 1 H NMR(400MHz, CDCl3)δ11.10(s,1H),7.92-7.85(m,1H),7.64-7.29(m,8H), 6.98(s,0.5H),6.83(d,1H),6.47(s,0.5H),5.05(s,J=7.8Hz,2H),4.23(s ,0.5H),3.94(m,2.5H),3.78-3.67(m,4.5H),3.37(m,0.5H),3.24(m,2H), 3.03(m,2H),2.18(s,J=2.5Hz,3H),2.00(s,3H),1.70(m,J=10.8Hz,12H).
[0104] Example 5 Synthesis of Compound RX005
[0105] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (18 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 738.4 [M+H]+; 1H NMR (400MHz, CDCl3) δ10.76(s,2H),8.19(t,J=6.0Hz,1H),7.90-7.82(m,1H),7.58-7.31(m,7H),7.25(d,J=15.3Hz,1H),6.92(d,J=8.7Hz,1H),6.30 -6.15(m,2H),5.16(s,2H),4.57(d,J=6.0Hz,2H),3.92(t,J=6.1Hz,2H),3 .73(s,2H),3.08(t,J=6.0Hz,2H),2.05(s,3H),2.00(s,3H),1.63(m,12H).
[0106] Example 6 Synthesis of Compound RX006
[0107] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (37 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 841.5 [M+H]+; 1 H NMR (400MHz, CDCl3) δ10.53 (s, 2H), 8.07-7.99 (m, 1H), 7.77 (d, J = 8.2Hz, 1H), 7.63-7.32(m,7H),6.92(d,J=8.7Hz,1H),5.19(s,2H),4.10(s,2H),4.00(m,1 H),3.89(s,2H),3.79-3.69(m,2H),3.10(t,J=6.0Hz,2H),2.92(t,J=12.6Hz, 2H),2.10(s,3H),2.01(s,3H),1.97(s,2H),1.77-1.63(m,14H),1.47(s,9H).
[0108] Example 7 Synthesis of Compound RX007
[0109] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (18.3 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 741.5 [M+H]+; 1 H NMR (400MHz, CDCl3) δ10.65(s,1H),7.93-7.81(m,1H),7.54(m,2H),7.45-7.31(m,5H ),7.26(t,J=7.6Hz,1H),6.81(d,J=8.8Hz,1H),5.03(s,2H),4.01(t,J=5.9Hz,2H),3 .73(s,2H),3.67-3.58(m,2H),3.12(t,J=5.0Hz,2H),3.04(t,J=6.0Hz,2H),2.29(t, J=5.2Hz,2H),2.20(ds,5H),2.07(t,J=5.2Hz,2H),2.01(s,3H),1.87-1.63(m,12H).
[0110] Example 8 Synthesis of Compound RX008
[0111] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 ml of DMF, TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added, and then compound B (34 mg, 0.1823 mmol) was added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 ml) was added and stirred for 1 h, and the filter cake was collected by filtration. The crude product was purified by silica gel column chromatography to obtain compound C. Compound C (85 mg, 0.1029 mmol) was dissolved in 1 ml of DCM, and HCl / dioxane (3 ml, 12 mmol) was added and allowed to react at room temperature for 2 h. The reaction solution was concentrated, and the crude product was slurried in ether (10 ml) for 5 h and filtered to dryness. MS (ESI) m / z = 727.4 [M+H]+; 1H NMR (400MHz, DMSO-d6) δ12.87(s,1H),9.36(s,2H),8.08(d,J=7.6Hz,1H),7.80(d,J =7.9Hz,1H),7.67-7.32(m,6H),7.25(s,1H),6.93(d,J=8.9Hz,1H),4.95(s,2H),3.8 6(t,J=5.9Hz,2H),3.73(s,2H),3.57(s,2H),3.28(t,J=5.1Hz,2H),3.02(t,J=6.0Hz ,2H),2.98(s,2H),2.78(s,2H),2.14(s,3H),2.00-1.88(s,3H),1.72-1.44(m,12H).
[0112] Example 9 Synthesis of Compound RX009
[0113] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (15.9 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 728.3 [M+H]+; 1 H NMR (400MHz, CDCl3) δ10.80 (s, 1H), 7.89-7.83 (m, 1H), 7.57 (d, J = 7.7, 1.3Hz, 1H), 7.49-7.30(m,6H),7.25(t,J=7.6Hz,1H),6.81(d,J=8.8Hz,1H),5.02(s,2H),3.99 (t,J=6.0Hz,2H),3.75(s,2H),3.64-3.53(dt,4H),3.35(dd,J=5.7,3.8Hz,2H),3. 12(t,J=4.7Hz,2H),3.04(t,J=6.0Hz,2H),2.20(s,3H),2.01(s,3H),1.73(m,12H).
[0114] Example 10 Synthesis of Compound RX010
[0115] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (21 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 756.5 [M+H]+; 1 H NMR(400MHz, CDCl3)δ10.56(s,1H),8.01(m,1H),7.91-7.81(m,1H),7.56(m,1H),7.50-7.4 2(m,2H),7.40(s,1H),7.39-7.32(m,3H),6.93(d,J=8.7Hz,1H),5.21(s,2H),3.97-3.86(m ,4H),3.73(s,2H),3.36-3.28(m,2H),3.26(t,J=6.8Hz,2H),3.10(t,J=6.0Hz,2H),2.08(s ,3H),2.00(s,3H),1.86(m,1H),1.70-1.63(m,12H),1.61-1.55(m,2H),1.32-1.26(m,2H).
[0116] Example 11 Synthesis of Compound RX011
[0117] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (21 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 756.5 [M+H]+; 1H NMR (400MHz, CDCl3) δ7.87(m,1H),7.62-7.49(m,2H),7.47-7.30(m,5H),7.25(m,1H),6.82(d,J=8.7Hz ,1H),5.20(d,J=17.3Hz,1H),4.94(d,J=17.3Hz,1H),4.58(d,J=13.2Hz,1H),4.06(m,1H),3.91(m,1H), 3.72(s,2H),3.48-3.40(m,2H),3.30(d,J=13.4Hz,1H),3.11-2.92(m,2H),2.76-2.64(m,1H),2.54-2.41(m,1H ),2.19(s,3H),2.00(s,3H),1.77-1.60(m,12H),1.37(m,J=15.3Hz,2H),1.32-1.27(m,2H),1.18-1.05(m,1H).
[0118] Example 12 Synthesis of Compound RX012
[0119] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (24 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 771.4 [M+H]+; 1 H NMR (400MHz, CDCl3) δ10.55 (s, 2H), 8.06 (d, J = 6.1Hz, 1H), 7.91-7.84 (m, 1H), 7.57 (d, J = 7. 5Hz,1H),7.52-7.43(m,2H),7.43-7.30(m,4H),6.93(d,J=8.7Hz,1H),5.13(s,2H),4.01(t, J=6.0Hz,2H),3.73(s,2H),3.72(dt,J=4.7Hz,4H),3.49(q,J=5.9,5.3Hz,2H),3.11(t,J=6. 0Hz,2H),2.57(t,J=6.3Hz,2H),2.50(m,4H),2.11(s,3H),2.00(s,3H),1.80-1.63(m,12H).
[0120] Example 13 Synthesis of Compound RX013
[0121] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (49 mg, 0.1519 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (24 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 771.3 [M+H] + ; 1 H NMR(400MHz, CDCl3)δ8.02(d,J=8.1Hz,1H),7.72(m,2H),7.57–7.49(m,2H),7.19(m,2H),7.04–6.94(m,2H),4.58(s,2H),4.18(m,2H),3 .66(m,4H),3.59(s,3H),3.63–3.53(m,2H),2.90(m,2H),2.55(m,2H),2.32(s,3H),2.21(m,4H),2.02(m,3H),1.71(m,12H),1.39(m,1H).
[0122] Example 14 Synthesis of Compound RX014
[0123] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (49 mg, 0.1519 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (11 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 702.2 [M+H] + ; 1H NMR(400MHz,Chloroform-d)δ8.34–8.31(m,1H),7.89–7.87(m,1H),7.76–7.64(m,2H),7.69 (s,1H),7.56(dd,J=7.5,2.0Hz,1H),7.36–7.27(m,1H),7.28–7.13(m,3H),7.05–6.93(m,2H ),4.58(s,2H),4.18(t,J=5.6Hz,2H),3.62–3.47(m,4H),3.14(t,J=3.9Hz,2H),2.90(td,J= 5.6,1.0Hz,2H),2.21(s,3H),2.10–1.94(m,3H),1.79–1.66(m,12H),1.34(t,J=5.0Hz,1H).
[0124] Example 15 Synthesis of Compound RX015
[0125] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (49 mg, 0.1519 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (14 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 716.2 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.20 (s, 1H), 8.09 (d, J = 8.0Hz, 1H), 7.74 (dd, J = 7.5, 1.6Hz, 1H), 7.73–7.64(m,1H),7.68(s,1H),7.54(dd,J=7.3,2.0Hz,1H),7.38–7.28(m,1H),7.26– 7.13(m,2H),7.05–6.93(m,2H),4.58(s,2H),4.18(t,J=5.6Hz,2H),3.60(d,J=3.9Hz, 4H),2.90(td,J=5.6,1.0Hz,2H),2.22(s,3H),2.10–1.95(m,3H),1.87–1.66(m,12H).
[0126] Example 16 Synthesis of Compound RX016
[0127] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 ml of DMF, TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added, and then compound B (42 mg, 0.1823 mmol) was added. The reaction was allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 ml) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography to obtain compound C. Compound C (90 mg) was dissolved in 1 ml of DCM, and HCl / dioxane (3 ml, 12 mmol) was added. The reaction was allowed to react at room temperature for 2 h. The reaction solution was concentrated, and the crude product was slurried in ether (10 ml) for 5 h and then filtered and dried. MS (ESI) m / z = 770.2 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.42-8.30(brs,1H),7.85-7.83(m,1H),7.62-7.58(m ,2H),7.39–7.23(m,6H),6.74(d,J=8.8Hz,1H),5.12(s,2H),3.90(m,2H),3. 69(s,2H),3.30-3.16(m,4H),3.08-3.05(m,2H),2.95-2.91(m,4H),2.47-2. 43(m,2H),2.22(s,3H),2.20-2.15(m,2H),1.97(s,3H),1.74-1.50(m,12H).
[0128] Example 17 to Example 22
[0129] The example compounds in the following Table 1 were prepared by the same methods as in the above examples, using commercially available compounds or referring to the preparation methods of the intermediate compounds shown.
[0130] Table 1
[0131] Example 23 Synthesis of Compound RX301
[0132] Phosphorus oxychloride (POCl3) (70 mg, 0.42 mmol) was diluted with pyridine (2 ml) and cooled to -15°C. RX002 (200 mg, 0.26 mmol) was dissolved in pyridine (1 ml) and added dropwise to the reaction mixture. The mixture was stirred at -15°C for 2 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). The reaction system was then warmed to -5°C, and water (3 ml) was slowly added. Stirring was continued for 1 h, and the pH was adjusted to 10 with 4 N NaOH. After oil pump concentration, the target product, RX301 sodium salt, was obtained by preparative purification using alkaline reverse-phase HPLC. MS (ESI) m / z = 850.5 [M+H] + ;1H NMR(400MHz, DMSO-d6)δ7.78(dd,J=6.2,3.0Hz,1H),7.69(d,J=7.7Hz,1H),7.55–7.40(m,2H),7.29– 7.11(m,4H),7.04(t,J=7.4Hz,1H),6.81(d,J=8.9Hz,1H),5.10(d,J=10.2Hz,2H),4.26(s,1H),3.81 (dd,J=14.2,7.4Hz,4H),3.42(s,3H),3.13(d,J=12.3Hz,1H),2.95(t,J=5.8Hz,2H),2.76–2.62(m,1 H),2.14(s,3H),1.92-1.85(m,2H),1.69–1.27(m,15H),1.23(t,J=8.1Hz,3H),1.06(t,J=7.0Hz,2H).
[0133] Example 24 Synthesis of Compound RX302
[0134] Step 1:
[0135] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (19 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 742.4 [M+H] + Step 2:
[0136] Phosphorus oxychloride (POCl3) (35 mg, 0.21 mmol) was diluted with pyridine (2 ml) and cooled to -15°C. C (100 mg, 0.13 mmol) was dissolved in pyridine (1 ml) and added dropwise to the reaction mixture. The reaction was stirred at -15°C for 2 hours. The reaction was monitored by TLC (DCM:MeOH = 10:1). The reaction system was then warmed to -5°C, and water (3 ml) was slowly added. Stirring was continued for 1 hour, and the pH was adjusted to 10 using 4 N NaOH. After oil pump concentration, the target product, RX302 sodium salt, was obtained by preparative purification using alkaline reverse-phase HPLC. MS (ESI) m / z = 822.5 [M+H] + ; 1 H NMR(400MHz, DMSO-d6)δ7.82(d,J=8.1Hz,1H),7.68–7.58(m,2H),7.49–7.34(m,3H),7.26–7.14( m,2H),6.99(td,J=7.5,1.6Hz,1H),4.35(s,2H),4.03–3.88(m,3H),3.61(ddt,J=34.5,12.4,7.0 Hz,2H),3.59(s,2H),2.95–2.83(m,3H),2.75(dt,J=12.4,7.1Hz,1H),2.46(s,3H),2.17–1.90(m,6H),1.82–1.61(m,14H).
[0137] Example 25 Synthesis of Compound RX303
[0138] Step 1:
[0139] Compound A-1331852 (100 mg, 0.1519 mmol) was dissolved in 5 mL of DMF, and TBTU (59 mg, 0.1823 mmol) and DIPEA (24 mg, 0.1823 mmol) were added. Compound B (48 mg, 0.1823 mmol) was then added and allowed to react at room temperature for 5 h. The reaction was monitored by TLC (DCM:MeOH = 10:1). H2O (50 mL) was added and stirred for 1 h. The filter cake was collected by filtration. The crude product was purified by silica gel column chromatography. MS (ESI) m / z = 904.5 [M+H] + Step 2:
[0140] Bromotrimethylsilane (77 mg, 0.50 mmol) was added dropwise to a solution of compound C (90 mg, 0.10 mmol) in dichloromethane (2 ml). The mixture was stirred at room temperature for 24 hours. The reaction was monitored by TLC (DCM:MeOH = 20:1). The reaction system was then cooled to 0°C, and water (5 ml) was slowly added. Stirring was continued for 1 hour, and the pH was adjusted to 10 with 4N NaOH. After oil pump concentration, the target product RX303 sodium salt was purified by alkaline reverse-phase preparative HPLC. MS (ESI) m / z = 848.5 [M+H]+; 1 H NMR(400MHz, DMSO-d6)δ7.85(d,J=7.9Hz,1H),7.70–7.58(m,2H),7.49–7.28(m,4H),7. 26–7.14(m,2H),7.00-6.96(m,1H),4.35(s,2H),4.00–3.88(m,3H),3.59(s,2H),3.52( dt,J=12.6,7.1Hz,1H),2.90(t,J=5.7Hz,3H),2.78-2.75(m,1H),2.46(s,3H),2.09–1. 93(m,3H),1.77–1.52(m,15H),1.44–1.28(m,2H),1.32–1.23(m,2H),1.27–1.13(m,4H).
[0141] Examples 26-30
[0142] According to the same method as the above examples, commercially available compounds or the preparation methods of the intermediate compounds shown in the reference were used to prepare the example compounds and their sodium salts in the following Table 2.
[0143] Table 2
[0144] Test Example 1: Solubility Test
[0145] The solubility test of the compounds of the present invention adopted the following test protocol:
[0146] 1). Accurately weigh the test compound, add the corresponding volume of pure water, and prepare the corresponding concentration (1 mg / mL or 10 mg / mL). Vortex and shake for 1 minute every 3 minutes for 15 minutes, observe the dissolution, let it stand for 1 hour, and then observe the dissolution. 2). Take 0.2 mL of 1 mg / mL compound or its sodium salt, add 1.8 mL of water, dilute to 0.1 mg / mL, vortex and shake for 5 minutes, observe the dissolution, let it stand for 1 hour, and then observe the dissolution. 3). Take 1 mL of 1 mg / mL compound or its sodium salt, add 1 mL of water, dilute to 0.5 mg / mL, vortex and shake for 5 minutes, observe the dissolution, let it stand for 1 hour, and then observe the dissolution.
[0147] The solubility test results are shown in Table 3 below.
[0148] Table 3
[0149] Conclusion: The solubility of compounds RX301 sodium salt, RX302 sodium salt, and RX303 sodium salt in water is greater than 10 mg / ml, which is significantly better than the solubility of A-1331852 sodium salt (the solubility of A-1331852 sodium salt is less than 0.1 mg / ml).
[0150] The above results indicate that the water solubility of the compound of the present invention is significantly improved compared to that of A-1331852 and A-1331852 sodium salt. Therefore, the compound of the present invention can be a useful drug with excellent drugability.
[0151] Test Example 2 Platelet Toxicity Test
[0152] In this test example, C57 mice were selected to detect the effect of the target compound on platelets.
[0153] 7-8 week old C56BL / 6J mice were randomly divided into vehicle group and compound group. The test compound (0.5 mg / kg) or blank solvent was injected intraperitoneally once. Blood was collected from the retroorbital venous plexus of the mice 6 hours later and placed in a routine blood test tube containing the anticoagulant EDTA-K2. After gentle shaking, blood physiological indicators were measured using a hematology analyzer. Platelet count was used as the target parameter of this platelet toxicity test.
[0154] As shown in Figure 1, A-1331852 has severe platelet toxicity, and the platelet toxicity of RX001-RX004, RX007-009, RX011, RX013, RX016, RX019, RX301, RX304, and RX307 is significantly improved compared with A-1331852.
[0155] Test Example 3: Senescent Cell Activity Data
[0156] This test case selected human non-small cell lung cancer cell lines (A549 cells), human embryonic lung fibroblast cell lines (IMR90 cells), human retinal pigment epithelial cells (RPE cells), mouse chondrocytes, and mouse skin fibroblasts. These cells were senescent by etoposide induction (10 μM). The effects of the target compounds on the viability of these normal and senescent cells were examined to evaluate the specific killing effect of the compounds on these senescent cells.
[0157] Briefly, the senescent and normal cells were plated (96-well plate) separately. After adding the compound (concentration of 1 μM) for 72 hours, the Cell viability was detected using the Luminescent Cell Viability Assay Kit (Promega), and the results are shown in Figures 2A to 2E.
[0158] As can be seen from Figures 2A to 2E, at a concentration of 1 μM, the compound can specifically kill senescent cells while having no obvious killing effect on normal cells.
[0159] Table 4 summarizes the cytotoxicity (IC) of the tested compounds against senescent cells. 50 ).
[0160] Table 4
[0161] Note: A represents less than 0.2μM; B represents: 0.2-1.0μM; C represents: 1-10μM; D represents greater than 10μM.
[0162] Test Example 4: Efficacy in an animal model of hyperoxia-induced retinopathy
[0163] The effects of prodrugs RX001-RX006 and RX301 were studied in an oxygen-induced retinopathy (OIR) mouse model, which is somewhat similar to an in vivo model of retinopathy of prematurity (ROP), diabetic retinopathy, and wet age-related macular degeneration.
[0164] From postnatal day 7 (P7) to day 12 (P12), C57Bl / 6 mouse pups and their CD1 foster mothers were exposed to a hyperoxic environment (75% O2). At P12, the animals were intravitreally injected with 1 μl of a test composition (200 μM compound) prepared in 1% DMSO, 10% Tween 80, 20% PEG-400 and returned to room air until day 17 (P17). At P17, the eyes were enucleated and the retinas dissected for vascular staining. To determine the area of avascularity or neovascularization, the retinas were flattened and stained with isolectin B4 (IB4).
[0165] Figure 3 shows that intravitreal (IVT) administration of RX001-RX006 and RX301 resulted in statistically significant improvements in avascular zone and vascular proliferation.
[0166] Test Example 5: Efficacy in an animal model of diabetic retinopathy
[0167] The efficacy of the compounds disclosed herein was studied in a mouse model of diabetic retinopathy by multiple administration of streptozotocin (STZ). C57BL / 6J mice aged 6 to 7 weeks were weighed and their baseline blood glucose (Sino) was measured. STZ (Sigma-Alderich) was injected intraperitoneally with 55 mg / Kg of mice for five consecutive days. Only buffer was injected into the age-matched control group. One week after the last STZ injection, blood glucose was measured again. 8 and 9 weeks after STZ administration, 1 μl of the test compound (200 uM, formulated as a suspension in 0.015% polysorbate 80, 0.2% sodium phosphate, 0.75% sodium chloride, pH 7.2) was injected into the vitreous of STZ-treated diabetic C57BL / 6J mice. Retinal Evans blue penetration assay was performed 10 weeks after STZ treatment.
[0168] Figure 4 shows retinal and choroidal vascular leakage following intravitreal (IVT) administration of RX001, RX002, RX003, and RX301, which all improved vascular permeability at this dose level.
[0169] Test Example 6: Efficacy in an Animal Model of CNV-Wet Age-Related Macular Degeneration
[0170] This example uses a CNV animal model to test the effects of the disclosed compounds on wet age-related macular degeneration.
[0171] Male mice were topically anesthetized with 0.5% propacaine hydrochloride (Alcon) and 1% tropicamide to dilate the pupils. Laser ablation was performed using a laser photocoagulator (Novus Varia, LUMENIS) with a slit-lamp delivery system. A manually ruptured glass coverslip was used as a contact lens. Laser-induced hemorrhages were not included in the statistical analysis. In each experimental group, six mice were analyzed, with four hits per eye, to overcome inherent variability.
[0172] Figure 5 shows statistically significant improvements in fluorescence intensity indices following intravitreal (IVT) administration of RX001, RX002, RX003, and RX301.
[0173] Test Example 7: Efficacy in an animal model of idiopathic pulmonary fibrosis
[0174] This example uses an idiopathic pulmonary fibrosis animal model to test the effects of the disclosed compounds on idiopathic pulmonary fibrosis.
[0175] In simple terms, anesthetized 6-week-old SD rats were fixed on a foam board with medical tape. First, the skin on the tracheal surface was cut open with surgical scissors to fully expose the trachea. A 100-microliter microinjection needle of a certain volume of bleomycin (BLM 5mg / kg) solution drawn according to the rat's weight was inserted into the trachea through the mouth for slow push administration. After the BLM solution was given, the foam board was immediately rotated and shaken to distribute the BLM solution evenly in the lung tissue as much as possible. The skin on the tracheal surface was then sutured with surgical sutures, and about 0.5-1.0ml of penicillin solution was dripped on the epidermis to prevent infection of the surgical wound. After the 7th day of modeling, the compound solution of the present invention was given according to the rat's weight and intraperitoneal injection (IP) was performed (5mg / kg) for 3 consecutive weeks.
[0176] On the 28th day, the rats were euthanized by carbon dioxide, and lung tissues were collected. The left alveolar lavage fluid was collected for white blood cell (WBC) count, the right lung tissue was partially tested for hydroxyproline (HYP), and the remaining lung tissue was subjected to pathological H&E staining and Masson staining.
[0177] Figure 6 shows that intraperitoneal (IP) administration of RX001, RX002, RX003, and RX301 resulted in statistically significant improvements in WBC, HYP, and pathology scores in the IPF model.
[0178] Test Example 8: Efficacy in an animal model of osteoarthritis
[0179] This example uses an osteoarthritis animal model to test the effects of the compounds of the present disclosure on osteoarthritis.
[0180] An osteoarthritis animal model was constructed by the following steps. The mice were anesthetized with isoflurane and fixed. The hair on the right hind limb of the mice was shaved, the skin was wiped and disinfected with alcohol, and the skin at the joint was cut. Under an optical microscope, the inner side of the right knee joint with the knee flexed was cut longitudinally with a blade. The patellar ligament was not cut. The patellar ligament was pulled to one side and compression was continuously applied with a sterile cotton swab to stop bleeding. The joint cavity was fully exposed and physiological saline was added in time to prevent the joint cavity from drying out. The excess muscle tissue was gently separated with blunt forceps to expose the meniscus ligament and the anterior cruciate ligament was searched deep in the joint cavity. The anterior cruciate ligament was cut open with micro-scissors, and the wound was disinfected with penicillin solution. The muscles were sutured with sterilized needles and thread, and finally the skin tissue was sutured. The efficacy of the drug was determined by intra-articular injection. At the end of the experiment, the plantar pain threshold was tested and the bone joints were stained with safranin and fast green.
[0181] FIG7 shows that intra-articular administration of RX001, RX002, RX003 and RX301 resulted in statistically significant improvements in plantar mechanical pain threshold and pathological scores of Safranin Fast Green staining in an osteoarthritis (OA) model.
[0182] Test Example 9: Efficacy in Alzheimer's disease animal models
[0183] This example uses an Alzheimer's disease animal model to test the effects of the disclosed compounds on Alzheimer's disease.
[0184] Briefly, an APP×PS1 transgenic mouse model (purchased from Saiye Bio) was selected and the disclosed compound was administered via intraperitoneal injection for 11 consecutive weeks, twice a week, to observe changes in amyloid protein in the mouse cerebral cortex.
[0185] FIG8 shows that intraperitoneal administration of RX001, RX002, RX003, and RX301 resulted in statistically significant improvement in Aβ42 pathogenic protein levels in the AD mouse model.
[0186] Test Example 10: Efficacy in an Animal Model of Liver Fibrosis
[0187] This example uses an animal model of liver fibrosis to test the effects of the compounds disclosed herein on liver fibrosis. Briefly, C57BL / 6N male mice, 7-8 weeks old, weighing 24-28g were selected. A mouse liver fibrosis model was induced by intraperitoneal injection of CCl4 solution at a dose of 1 ml / kg, twice a week, and a modeling period of 6 weeks. Intraperitoneal injection was started in the third week of modeling, and administration was performed twice a week. Serum was collected at the end of the experiment, and liver tissue was taken for Masson staining index detection.
[0188] FIG9 shows that intraperitoneal (IP) administration of RX001 and RX301 resulted in statistically significant improvements in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and pathology scores in a liver fibrosis model.
[0189] Test Example 11: Effect on aging skin
[0190] This example used elderly female C57bl / 6J mice (22 months old). The drug was administered via skin application twice weekly for 6 consecutive weeks. The improvement in epidermal thickness of the elderly mice was observed.
[0191] Figure 10 shows that topical application of RX001, RX002, RX003, and RX301 resulted in statistically significant improvements in epidermal thickness scores in a natural aging mouse model.
[0192] Test Example 12: Efficacy in Renal Fibrosis Animal Model
[0193] This embodiment uses a renal fibrosis animal model to test the effect of the compounds disclosed herein on renal fibrosis. Briefly, C57BL / 6J male mice, 7-8 weeks old, were selected. After being anesthetized, the mice were placed supine on a foam board, disinfected with iodine, and a longitudinal incision was made in the middle of the lower abdomen to find the white line of the abdominal muscles. The abdominal muscles, fascia, and peritoneum were cut open here. After exposing the surgical field, the stomach and mesentery of the mice were pushed to the right side with gauze soaked in normal saline to expose the kidney. From the renal pelvis, the transparent ureter was found along the renal artery, the left ureter was separated, and the upper 1 / 3 of the left ureter was ligated. The incision was sutured layer by layer, and finally disinfected with iodine to construct a renal fibrosis model. Intraperitoneal injection was performed starting from the second week of modeling. Mouse serum was collected at the end of the experiment, and kidney tissue was taken for Masson staining index detection.
[0194] Figure 11 shows that intraperitoneal (IP) administration of RXOOl and RX301 resulted in statistically significant improvements in serum creatinine (Cr) and urea nitrogen (BUN) levels and pathology in a renal fibrosis model.
[0195] Test Example 13: Efficacy in the rabbit ear hypertrophic scar model
[0196] This embodiment uses a rabbit ear hypertrophic scar animal model to test the effect of the disclosed compounds on hypertrophic scars. Briefly, 15 male New Zealand white rabbits, 3 months old, were selected. After the New Zealand rabbits were anesthetized with sodium pentobarbital, 6 circular full-thickness wounds with a diameter of 10 mm were made on the ventral surface of each ear by removing the epidermis, dermis and perichondrium to the exposed cartilage. The rabbits were randomly divided into a control group, an RX001 experimental group and an RX301 experimental group. On the 14th day after surgery, after the wound was completely re-epithelialized, the compound (150uM, 100ul, dissolved in DMSO solution) or negative control DMSO 100ul was taken and the solution was injected from the edge of the wound into the center of each lesion, once a week, for a total of 4 injections. The improvement of scar formation by the drug was evaluated by SEI (scar hyperplasia index).
[0197] FIG12 shows that administration of RX001 and RX301 resulted in statistically significant improvement in the scar hyperplasia index in the rabbit ear hypertrophic scar model.
Claims
1. A benzothiazole compound having a structure as shown in Formula I, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer or isotope thereof, in, R1 and R2 are independently selected from C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl, C2-C20 heteroalicyclic, wherein CH2 in C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl can be selected from one of -O-, -S-, -SO2-, -C(O)- and -NR3- or two or more groups, the C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic groups are optionally replaced by halogen atoms, cyano, nitro, C6-C20 aryl, C1-C20 heteroaryl, C1-C10 alkoxy, C6-C20 aryloxy, C2-C20 heteroalicyclic groups, amino, hydroxyl, thiol, -substituted by one or more substituents in NR4R5; or R1 and R2 together with the nitrogen atom to which they are attached constitute a heteroalicyclic group, preferably a C2-C20 heteroalicyclic group; or R1 is hydrogen, and R2 is selected from C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic group, wherein CH2 in C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl can be replaced by one or more groups selected from -O-, -S-, -SO2-, -C(O)- and -NR3-, and the C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl groups are selected from C6-C20 aryl, C1-C20 heteroaryl and C2-C20 heteroalicyclic group. 8-cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C6-C20 aryl, C1-C20 heteroaryl, or C2-C20 heteroalicyclic group is substituted by a halogen atom, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, C1-C10 alkoxy, C6-C20 aryl, C1-C20 heteroaryl, C2-C20 heteroalicyclic group, C1-C10 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl, and the substituents at at least two positions together form an aliphatic ring, heteroalicyclic ring, aromatic ring, or heteroaromatic ring; R3, R4 and R5 are independently selected from hydrogen, aryl, heteroaryl, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl, wherein the aryl and heteroaryl groups are optionally substituted with halogen atoms, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, alkoxy, aryl, heteroaryl, heteroalicyclic, C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl or C2-C8 alkynyl, wherein the substituents at at least two positions together form an alicyclic, heteroalicyclic, aromatic or heteroaromatic ring; L is a C1-C6 alkylene group, which is optionally substituted by a halogen atom, a hydroxyl group, a mercapto group, an amino group, a nitro group, a cyano group, a carboxyl group, an acyl group, a C1-C10 Alkoxy, C6-C20 aryl, C1-C20 heteroaryl, C2-C20 heteroalicyclic, C1-C10 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl or C2-C8 alkynyl substitution; R is an adamantyl group, which is optionally substituted with a halogen atom, a hydroxyl group, a mercapto group, an amino group, a nitro group, a cyano group, a carboxyl group, an acyl group, a C1-C10 alkoxy group, a C6-C20 aryl group, a C1-C20 heteroaryl group, a C2-C20 heteroalicyclic group, a C1-C10 alkyl group, a C3-C8 cycloalkyl group, a C2-C8 alkenyl group, or a C2-C8 alkynyl group; R a 、R b 、R c 、R d 、R e 、R f 、R g 、R h 、R i 、R j 、R k 、R l 、R m 、R p 、R q 、R z Each is independently selected from hydrogen, halogen-substituted or unsubstituted C1-C8 alkyl, halogen-substituted or unsubstituted C3-C8 cycloalkyl, halogen-substituted or unsubstituted C2-C8 alkenyl, halogen-substituted or unsubstituted C2-C8 alkynyl, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, an acyl group, a halogen-substituted or unsubstituted C2-C8 alkoxy group.
2. The compound according to claim 1, characterized in that The compound is shown in Formula II: In formula II, the definitions of R1 and R2 are the same as those in formula I.
3. The compound according to claim 1 or 2, characterized in that R1 and R2 together with the nitrogen atom to which they are attached constitute a C2-C20 heteroalicyclic group, such as a C2-C10 heteroalicyclic group, wherein the ring of the C2-C20 heteroalicyclic group optionally contains 1 or 2 heteroatoms selected from N or O. The C2-C20 heteroalicyclic group is optionally substituted by a halogen atom, a cyano group, a nitro group, a C6-C10 aryl group, a C1-C10 heteroaryl group, a C1-C6 alkoxy group, a C6-C10 aryloxy group, a C2-C10 heteroalicyclic group, an amino group, a hydroxyl group, a thiol group, a carbonyl group, a carboxyl group, an acyl group, -NR4R5 is substituted by one or more substituents, R4 and R5 are independently selected from hydrogen, C6-C10 aryl, C1-C10 heteroaryl, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl and C2-C8 alkynyl, and the aryl and heteroaryl groups are optionally substituted by halogen atoms, hydroxyl, sulfhydryl, amino, nitro, cyano, carboxyl, acyl, C1-C8 alkoxy, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic group, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C6 alkenyl or C2-C8 alkynyl, optionally, wherein the substituents at at least two positions together constitute a C3-C10 alicyclic ring, C2-C10 heteroalicyclic ring, C6-C10 aromatic ring or C1-C10 heteroaromatic ring; For example, the C2-C20 heteroalicyclic group is optionally selected from a halogen atom, a hydroxyl group, a mercapto group, an amino group, a nitro group, a cyano group, a C1-C10 alkoxy group, a C1-C10 alkyl group, a C3-C8 cycloalkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, Substituents are substituted, R4 and R5 are independently selected from hydrogen and C1-C6 alkyl; For example, the C2-C8 heteroalicyclic group is optionally substituted by a group selected from halogen, -NH2, -OH, -NO2, carbonyl, -CH2OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
4. The compound according to claim 1 or 2, characterized in that R1 and R2 are independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic, wherein CH2 in C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl can be selected from one of -O-, -S-, -SO2-, -C(O)- and -NR3- or two or more groups, the C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl, C1-C10 heteroaryl and C2-C10 heteroalicyclic group are optionally replaced by halogen atoms, cyano, nitro, C6-C10 aryl, C1-C10 heteroaryl, C1-C6 alkoxy, C6-C10 aryloxy, C2-C10 heteroalicyclic group, amino, hydroxyl, thiol, -NR4R5 is substituted by one or more substituents, R3, R4 and R5 are independently selected from hydrogen, C6-C10 aryl, C1-C10 heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl and C2-C6 alkynyl, and the aryl and heteroaryl are optionally substituted by halogen atoms, hydroxyl, thiol, amino, nitro, cyano, carboxyl, acyl, C1-C6 alkoxy, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic group, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl or C2-C6 alkynyl, wherein the substituents at at least two positions together constitute a C3-C10 alicyclic ring, C2-C10 heteroalicyclic ring, C6-C10 aromatic ring or C1-C10 heteroaromatic ring.
5. The compound according to any one of claims 1 to 4, characterized in that The compound is shown in formula III: R2 is a C1-C10 alkyl group, a C3-C8 cycloalkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C6-C20 aryl group, a C1-C20 heteroaryl group and a C2-C20 heteroalicyclic group, wherein the CH2 in the C1-C10 alkyl group, the C3-C8 cycloalkyl group, the C2-C8 alkenyl group and the C2-C8 alkynyl group can be replaced by one or more groups selected from -O-, -S-, -SO2-, -C(O)- and -NR3-, and the C1-C10 alkyl group, the C3-C8 cycloalkyl group, the C2-C8 alkenyl group, the C2-C8 alkynyl group, the C6-C20 aryl group, the C1-C20 heteroaryl group and the C2-C20 heteroalicyclic group can be replaced by halogen atoms, cyano groups, nitro groups, C6-C20 Aryl, C1-C20 heteroaryl, C1-C10 alkoxy, C6-C20 aryloxy, C2-C20 heteroalicyclic, amino, hydroxy, mercapto, -NR4R5 is substituted by one or more substituents; R3, R4 and R5 are independently selected from hydrogen, C6-C10 aryl, C1-C10 heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl and C2-C6 alkynyl, and the aryl and heteroaryl are optionally substituted by halogen atoms, hydroxyl, sulfhydryl, amino, nitro, cyano, carboxyl, acyl, C1-C6 alkoxy, C6-C10 aryl, C1-C10 heteroaryl, C2-C10 heteroalicyclic group, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl or C2-C6 alkynyl, wherein the substituents at at least two positions together constitute a C3-C10 alicyclic ring, C2-C10 heteroalicyclic ring, C6-C10 aromatic ring or C1-C10 heteroaromatic ring.
6. The compound according to any one of claims 1 to 5, characterized in that The heteroalicyclic group or heteroalicyclic ring is selected from the group consisting of substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted piperazin-2-onyl, substituted or unsubstituted pyrrolidinyl and substituted or unsubstituted imidazolinyl.
7. The compound according to any one of claims 1 to 6, characterized in that R1 and / or R2 are selected from methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, vinyl, 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heterocyclyl, 6-membered heterocyclyl, 5-membered carbocyclyl or 6-membered carbocyclyl, and each heteroaryl and each heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and each group is independently optionally substituted by -F, -Cl, -Br, -I, -NH2, -OH, -NO2, carbonyl, -CH2-OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
8. The compound according to any one of claims 1 to 7, characterized in that R1 and / or R2 are selected from 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, 5-membered heterocyclyl, 6-membered heterocyclyl, 5-membered carbocyclyl or 6-membered carbocyclyl, and each heteroaryl and each heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and each group is independently optionally substituted with -F, -Cl, -Br, -I, -NH2, -OH, -NO2, carbonyl, =O, -CH2-OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; Or R1 and R2 together with the N atom to which they are attached constitute a 6-membered aryl, a 5-membered heteroaryl, a 6-membered heteroaryl, a 5-membered heterocyclyl, a 6-membered heterocyclyl, a 5-membered carbocyclyl or a 6-membered carbocyclyl, and each heteroaryl and each heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and each group is independently optionally substituted by -F, -Cl, -Br, -I, -NH2, -OH, -NO2, carbonyl, =O, -CH2-OH, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.
9. The compound according to any one of claims 1 to 8, characterized in that R1 and R2 together with the nitrogen atom to which they are attached constitute a C2-C20 heteroalicyclic group; and / or The heteroalicyclic group is selected from C4-C20 heteroalicyclic groups, Preferably, the C4-C20 heteroalicyclic group is selected from: a substituted or unsubstituted morpholinyl group, a substituted or unsubstituted piperidinyl group, or a substituted or unsubstituted piperazinyl group; Preferably, the C4-C20 heteroalicyclic group is selected from the following groups: R' independently represents no substituent, a single substituent or multiple substituents, each substituent is independently selected from deuterium, hydroxyl, halogen, NH2, carboxyl (-COOH), C1-C6 alkyl, halogen-substituted C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl, benzyl; L2 is absent or C1-C6 alkylene, halogen, hydroxyl, C1-C6 alkoxy substituted C1-C6 alkylene, preferably methylene, ethylene, propylene; R6 is H, deuterium, halogen, hydroxyl, NH2, carboxyl (-COOH), -CONH2, sulfonic acid (-SO3H), -SO2-C1-C6 chain alkyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl or benzyl.
10. The compound according to claim 1, characterized in that The compound has a structure shown in Formula I-1, Formula I-2, Formula I-3, Formula I-4 or Formula I-5, L1 is absent or -NHL3-, L3 is absent or L2 is absent C1-C6 alkylene, halogen, hydroxyl, C1-C6 alkoxy substituted C1-C6 alkylene, preferably methylene, ethylene, propylene; L2 is a C1-C6 alkylene group not substituted by a C1-C6 alkylene group, a halogen group, a hydroxyl group, or a C1-C6 alkoxy group, preferably a methylene group, an ethylene group, or a propylene group; R6 is H, deuterium, halogen, hydroxyl, NH2, carboxyl (-COOH), -CONH2, sulfonic acid (-SO3H), -SO2-C1-C6 chain alkyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl or benzyl; R' independently represents no substituent, a single substituent or multiple substituents, each substituent is independently selected from R6 is H, deuterium, halogen, hydroxyl, NH2, carboxyl (-COOH), -CONH2, sulfonic acid (-SO3H), -SO2-C1-C6 chain alkyl, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, morpholine-substituted C1-C6 alkyl, -COO-C1-C6 alkyl, cyano, C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C3-C6 cycloalkyl, halogen-substituted C3-C6 cycloalkyl, hydroxy-substituted C3-C6 cycloalkyl, phenyl or benzyl; Other symbols are defined the same as in Formula I.
11. The compound according to any one of claims 1 to 10, characterized in that R a 、R b 、R c 、R d Each independently selected from hydrogen or C1-C6 alkyl; and / or R e 、R f 、R g Each independently selected from hydrogen or C1-C6 alkyl; and / or R h 、R i 、R j 、R k 、R l 、R m Each independently selected from hydrogen or C1-C6 alkyl; and / or R p 、R q 、R z Each independently selected from hydrogen or C1-C6 alkyl; and / or L is methylene; and / or R Z is methyl; and / or R is 12. The compound according to claim 10 or 11, characterized in that L1 does not exist; and / or R6 is H, halogen, hydroxyl, NH2, carboxyl, C1-C3 alkyl, halogen-substituted C1-C3 alkyl or hydroxy-substituted C1-C3 alkyl; Preferably, R6 is 13. The compound according to any one of claims 1 to 12, characterized in that The benzothiazole compound is selected from the following compounds:
14. The compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer or isotope thereof, characterized in that: The salt of the compound is an alkali metal salt, preferably a sodium salt.
15. A pharmaceutical composition comprising the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer or isotope thereof, and a pharmaceutically acceptable excipient.
16. A method for preventing or treating a disease associated with aging, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer or isotope thereof, or the pharmaceutical composition of claim 15.
17. The method according to claim 16, characterized in that The disease is selected from diseases associated with the accumulation of senescent cells, preferably selected from idiopathic pulmonary fibrosis, pulmonary fibrosis, liver fibrosis, renal fibrosis, viral-induced inflammation and tissue fibrosis and atrophy of the upper respiratory tract and lungs, cystic fibrosis, myelofibrosis, myocardial fibrosis, skin fibrosis, interstitial lung disease, fibrosing pancreatitis, retinopathy of prematurity, macular degeneration, diabetic macular edema, diabetic retinopathy, age-related macular degeneration, wet age-related macular degeneration, dry age-related macular degeneration, glaucoma, sickle cell retinopathy, ischemic arteritic neuropathy, keratitis sicca, Fuch's corneal dystrophy, presbyopia, cataracts, degenerative vitreous disorders including vitreomacular traction syndrome, macular hole, retinal tear, retinal detachment, proliferative vitreoretinopathy, osteoarthritis, herniated disc, osteoporosis, Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic obstructive pulmonary disease, diabetes , diabetic nephropathy, scars, superficial scars or flat scars, cord-like scars or contracture scars, webbed scars, depressed scars, atrophic scars, bridge-like scars and hypertrophic scars, hypertrophic scars, keloids, scar cancer, scleroderma, morphea, scleroderma bands, guttate scleroderma, acroscleroderma, diffuse scleroderma, CREST syndrome, acute coronary syndrome, myocardial infarction, stroke, hypertension, obesity, fat dysfunction, coronary artery disease, cerebrovascular disease, One or more of periodontal disease, cancer treatment-related disabilities such as atrophy and fibrosis in various tissues, brain and heart damage and treatment-related myelodysplastic syndrome, promyeloid syndrome, ataxia-telangiectasia, Fanconi anemia, Friedreich's ataxia, dyskeratosis congenita, aplastic anemia, aneurysms, inflammatory bowel disease, lipoatrophy, renal transplant failure, sarcopenia, wound healing, alopecia, cardiomyocyte hypertrophy, glomerulosclerosis, and cancer.
18. Use of the compound according to any one of claims 1 to 14 or its pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer or isotope compound, or the pharmaceutical composition according to claim 15 in the preparation of a medicament for preventing or treating aging-related diseases.
19. The use according to claim 15, wherein: The disease is selected from diseases associated with the accumulation of senescent cells, preferably selected from idiopathic pulmonary fibrosis, pulmonary fibrosis, liver fibrosis, renal fibrosis, viral-induced inflammation and tissue fibrosis and atrophy of the upper respiratory tract and lungs, cystic fibrosis, myelofibrosis, myocardial fibrosis, skin fibrosis, interstitial lung disease, fibrosing pancreatitis, retinopathy of prematurity, macular degeneration, diabetic macular edema, diabetic retinopathy, age-related macular degeneration, wet age-related macular degeneration, dry age-related macular degeneration, glaucoma, sickle cell retinopathy, ischemic arteritic neuropathy, keratitis sicca, Fuch's corneal dystrophy, presbyopia, cataracts, degenerative vitreous disorders including vitreomacular traction syndrome, macular hole, retinal tear, retinal detachment, proliferative vitreoretinopathy, osteoarthritis, herniated disc, osteoporosis, Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic obstructive pulmonary disease, diabetes , diabetic nephropathy, scars, superficial scars or flat scars, cord-like scars or contracture scars, webbed scars, depressed scars, atrophic scars, bridge-like scars and hypertrophic scars, hypertrophic scars, keloids, scar cancer, scleroderma, morphea, scleroderma bands, guttate scleroderma, acroscleroderma, diffuse scleroderma, CREST syndrome, acute coronary syndrome, myocardial infarction, stroke, hypertension, obesity, fat dysfunction, coronary artery disease, cerebrovascular disease, One or more of periodontal disease, cancer treatment-related disabilities such as atrophy and fibrosis in various tissues, brain and heart damage and treatment-related myelodysplastic syndrome, promyeloid syndrome, ataxia-telangiectasia, Fanconi anemia, Friedreich's ataxia, dyskeratosis congenita, aplastic anemia, aneurysms, inflammatory bowel disease, lipoatrophy, renal transplant failure, sarcopenia, wound healing, alopecia, cardiomyocyte hypertrophy, glomerulosclerosis, and cancer.
